Bank of New York Mellon’s Abeona Therapeutics ABEO Stock Holding History

Bank of New York Mellon’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26M	Buy	204,246 +10,614	+5%	+$58.3K	﹤0.01%	3222
2026 Q1	$867K	Sell	193,632 -632	-0.3%	-$3.16K	﹤0.01%	3292
2025 Q4	$1.02M	Sell	194,264 -19,578	-9%	-$98.6K	﹤0.01%	3219
2025 Q3	$1.13M	Buy	213,842 +1,663	+0.8%	+$10.5K	﹤0.01%	3141
2025 Q2	$1.21M	Buy	212,179 +90,727	+75%	+$516K	﹤0.01%	3030
2025 Q1	$578K	Hold	121,452	–	–	﹤0.01%	3379
2024 Q4	$676K	Hold	121,452	–	–	﹤0.01%	3366
2024 Q3	$768K	Sell	121,452 -1	-0%	-$5	﹤0.01%	3281
2024 Q2	$515K	Buy	121,453 +2,434	+2%	+$12.4K	﹤0.01%	3572
2024 Q1	$863K	Buy	119,019 +105,699	+794%	+$670K	﹤0.01%	3230
2023 Q4	$66.7K	Buy	13,320 +386	+3%	+$1.7K	﹤0.01%	4139
2023 Q3	$54.5K	Hold	12,934	–	–	﹤0.01%	4156
2023 Q2	$52.1K	Buy	+12,934	New	+$45.2K	﹤0.01%	4173
2022 Q3	–	Sell	-1,763	Closed	-$9K	–	4549
2022 Q2	$9K	Hold	1,763	–	–	﹤0.01%	4554
2022 Q1	$14K	Hold	1,763	–	–	﹤0.01%	4629
2021 Q4	$15K	Sell	1,763 -2,153	-55%	-$39.5K	﹤0.01%	4600
2021 Q3	$110K	Hold	3,916	–	–	﹤0.01%	4316
2021 Q2	$153K	Sell	3,916 -7,053	-64%	-$288K	﹤0.01%	4148
2021 Q1	$516K	Sell	10,969 -260	-2%	-$14.3K	﹤0.01%	3669
2020 Q4	$441K	Buy	11,229 +798	+8%	+$27.2K	﹤0.01%	3677
2020 Q3	$266K	Sell	10,431 -326	-3%	-$20.6K	﹤0.01%	3761
2020 Q2	$784K	Buy	10,757 +798	+8%	+$55.2K	﹤0.01%	3242
2020 Q1	$524K	Buy	9,959 +1,968	+25%	+$131K	﹤0.01%	3340
2019 Q4	$652K	Buy	7,991 +2,114	+36%	+$149K	﹤0.01%	3453
2019 Q3	$333K	Sell	5,877 -472	-7%	-$35.3K	﹤0.01%	3742
2019 Q2	$759K	Buy	6,349 +760	+14%	+$127K	﹤0.01%	3377
2019 Q1	$1.03M	Sell	5,589 -1	-0%	-$179	﹤0.01%	3157
2018 Q4	$998K	Sell	5,590 -122	-2%	-$26.6K	﹤0.01%	3104
2018 Q3	$1.83M	Buy	5,712 +51	+0.9%	+$18.1K	﹤0.01%	2892
2018 Q2	$2.27M	Sell	5,661 -35	-0.6%	-$15.3K	﹤0.01%	2788
2018 Q1	$2.04M	Sell	5,696 -2,123	-27%	-$789K	﹤0.01%	2791
2017 Q4	$3.1M	Buy	7,819 +3,699	+90%	+$1.53M	﹤0.01%	2594
2017 Q3	$1.76M	Buy	4,120 +120	+3%	+$32.2K	﹤0.01%	2913
2017 Q2	$640K	Buy	4,000 +2,323	+139%	+$317K	﹤0.01%	3485
2017 Q1	$210K	Buy	1,677 +934	+126%	+$120K	﹤0.01%	3865
2016 Q4	$90K	Buy	+743	New	+$116K	﹤0.01%	4041
2016 Q2	–	Sell	-823	Closed	-$53K	–	4318
2016 Q1	$53K	Buy	823 +77	+10%	+$5.1K	﹤0.01%	4071
2015 Q4	$63K	Buy	746 +11	+1%	+$1.1K	﹤0.01%	4147
2015 Q3	$74K	Sell	735 -312	-30%	-$41.4K	﹤0.01%	4185
2015 Q2	$132K	Buy	+1,047	New	+$157K	﹤0.01%	3986

Other funds holding ABEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

Bank of New York Mellon's ABEO Position: Q2 2026 in Review

Bank of New York Mellon increased its Abeona Therapeutics (ABEO) stake by 5.5% in Q2 2026, buying an estimated $58.3K and bringing the position to 204,246 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

Bank of New York Mellon first reported a position in ABEO in Q2 2015 and has held it in 40 quarters since. The position peaked at $3.1M in Q4 2017. 50 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Bank of New York Mellon held 204,246 shares of Abeona Therapeutics worth $1.26M as of Q2 2026.
Bank of New York Mellon bought 10,614 Abeona Therapeutics shares in Q2 2026, an estimated $58.3K.
Abeona Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3222 holding.
Bank of New York Mellon first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 40 quarters since.
Bank of New York Mellon's Abeona Therapeutics position peaked at $3.1M in Q4 2017.
50 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.